Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-na ïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)

ConclusionsThe potential treatment efficacy of this triplet regimen in HER2-negative advanced gastric cancer warrants further evaluation, especially in patients requiring intensive chemotherapy.

Source: International Journal of Clinical Oncology - July 7, 2023 Category: Cancer & Oncology Source Type: research